This optimized glycosylated-PEG-oHSV selectively infected and killed cancer cells by targeting the asialoglycoprotein receptor (ASGPR) present in HCC cells 37, while efficiently reducing oHSV-neutralizing antibody levels and decreasing the number of regulatory T-cells within the TME after systemic administration. This evidence concerns the gene ASGR1 and hepatocellular carcinoma.